- Large-scale genome-wide association study to determine the genetic underpinnings of 1
- 2 female genital tract polyps
- 3 **Running title:** GWAS of female genital tract polyps
- Amruta D. S. Pathare^{1,3†*}, Natàlia Pujol-Gualdo^{2†}, Valentina Rukins², Jelisaveta Džigurski², 4
- Maire Peters^{1,3}, Estonian Biobank Research Team, Reedik Mägi², Andres Salumets^{1,3,4}, Merli 5
- Saare^{1,3}, Triin Laisk² 6
- 7 1 Competence Centre on Health Technologies, Tartu, Estonia
- 8 2 Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 9 3 Department of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of
- Tartu, Tartu, Estonia 10
- 4 Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and 11
- Technology (CLINTEC), Karolinska Institute and Karolinska University Hospital, Stockholm, 12
- 13 Sweden

17

- *Corresponding author: Amruta D. S. Pathare, amruta.pathare@ut.ee ORCID No: 0000-14
- 15 0002-5608-2370

^{ាំ} Nortea แต่เลงกระเวณกระเดอกร่างสหารและ the characteristics process continues a particular and interest to guide clinical practice.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

2

18 Abstract 19 STUDY QUESTION 20 Can a large-scale genome-wide association study (GWAS) meta-analysis identify the genomic 21 risk loci and associated candidate genes for female genital tract (FGT) polyps, provide insights into the mechanism underlying their development, and inform potential overlap with other 22 23 traits, including endometrial cancer? 24 **SUMMARY ANSWER** 25 GWAS meta-analysis of FGT polyps highlighted the potentially shared mechanisms between polyp development and cancerous processes. 26 27 WHAT IS KNOWN ALREADY 28 Small-scale candidate gene studies have focused on biological processes such as estrogen stimulation and inflammation to clarify the biology behind FGT polyps. However, the exact 29 30 mechanism for the development of polyps is still elusive. At the same time, a genome-wide approach, which has become the gold standard in complex disease genetics, has never been 31 32 used to uncover the genetics of the FGT polyps. 33 STUDY DESIGN, SIZE, DURATION We performed a genome wide association study (GWAS) meta-analysis including a total of 34 35 25,100 women with FGT polyps (International Classification of Disease, ICD-10 diagnosis 36 code N84) and 207,193 female controls (without N84 code) of European ancestry from the 37 FinnGen study (11,092 cases and 94,394 controls) and the Estonian Biobank (EstBB, 14,008

38

cases and 112,799 controls).

prioritise genes in associated loci. To determine associations with other phenotypes, we

performed a look-up of associated variants across multiple traits and health conditions, a genetic

correlation analysis, and a phenome-wide association study (PheWAS) with ICD10 diagnosis

codes.

39

41

42

43

44

45

47

48

49

50

51

52

53

54

55

56

57

58

MAIN RESULTS AND THE ROLE OF CHANCE

Our GWAS meta-analysis revealed ten significant ($P < 5 \times 10^{-8}$) genomic risk loci. Two signals, 46

rs2277339 (P = 7.6 x 10^{-10}) and rs1265005 (P = 1.1 x 10^{-9}) (in linkage disequilibrium (LD) with

rs805698 $r^2 = 0.75$), are exonic missense variants in *PRIM1*, and *COL17A1* genes, respectively.

Based on the literature, these genes may play a role in cellular proliferation. Several of the

identified genomic loci had previously been linked to endometrial cancer and/or uterine

fibroids. Thus, highlighting the potentially shared mechanisms underlying tissue overgrowth

and cancerous processes, which may be relevant to the development of polyps. Genetic

correlation analysis revealed a negative correlation between sex hormone-binding globulin

(SHBG) and the risk of FGT polyps (rg = -0.21, se = 0.04, P = 2.9×10^{-6}), and on the phenotypic

level (PheWAS), the strongest associations were observed with endometriosis, leiomyoma of

the uterus and excessive, frequent and irregular menstruation.

LARGE SCALE DATA

- The complete GWAS summary statistics will be made available after publication through the
- GWAS Catalogue (https://www.ebi.ac.uk/gwas/). 59

LIMITATIONS, REASONS FOR CAUTION 60

In this study, we focused broadly on polyps of FGT and did not differentiate between the polyp subtypes. The prevalence of FGT polyps led us to assume that most women included in the study had endometrial polyps. Further study on the expression profile of FGT polyps could complement the GWAS study to substantiate the functional importance of the identified variants.

WIDER IMPLICATIONS OF THE FINDINGS

The study findings have the potential to significantly enhance our understanding of the genetic mechanisms involved, paying the way for future functional follow-up, which in turn could improve the diagnosis, risk assessment, and targeted treatment options, since surgery is the only line of treatment available for diagnosed polyps.

TRIAL REGISTRATION NUMBER:

Not applicable 72

61

62

63

64

65

66

67

68

69

70

71

76

77

78

79

80

81

82

- 73 Key words: Genome-wide association study, Female genital tract polyps, Endometrial polyps,
- Benign disorders, cell proliferation, PRIM1, COL17A1. 74

75 Introduction

Polyps of the female genital tract (FGT) are generally benign tissue overgrowths found in both reproductive-aged and postmenopausal women. While the prevalence of polyps can be as high as 50%, most women are asymptomatic. Hence, polyps are usually detected incidentally during routine ultrasound examinations, diagnostic hysteroscopy for other gynaecological disorders, or infertility treatment among women of reproductive age (Hinckley and Milki, 2004; Fatemi et al., 2010; Karayalcin et al., 2010; Bettocchi et al., 2011). However, the occurrence of polyps is age-dependent, with a higher prevalence among postmenopausal women compared

to premenopausal women (Dreisler et al., 2009). Despite the asymptomatic and benign nature of FGT polyps, for some women, they can negatively impact the daily quality of life by causing abnormal vaginal bleeding and infertility.

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

Endometrial polyps (EPs) are the most common type of FGT polyps, with a prevalence ranging from 7.8% to 50% (Dreisler et al., 2009; de Azevedo et al., 2016; Tanos et al., 2017). In contrast, endocervical polyps occur only in 2% to 5% of cases, whereas vaginal polyps are rarer (Tanos et al., 2017); therefore, limited evidence is available about their biology and clinical implications. Some known risk factors for the development of EPs are advanced age, hypertension, diabetes, obesity, hyperoestrogenism, administration of hormone replacement therapy (HRT), and tamoxifen (Vitale et al., 2021; Vieira et al., 2022). Nevertheless, the exact pathogenesis of FGT polyps remains unclear. Histologically, EPs are characterised by large, thickened blood vessels with fibrous stroma and irregularly shaped glandular spaces (Tanos et al., 2017). Moreover, EPs can be associated with concomitant intrauterine pathologies like endometrial hyperplasia, adenomyosis, endometriosis and chronic endometritis (Annan et al., 2012; Raz et al., 2021). Despite the benign nature of EPs, around 3.5% of cases progress into carcinoma (Lee et al., 2010; Sasaki et al., 2018; Uglietti et al., 2019). At the same time, the extent of biological mechanisms and pathways shared between EPs and carcinoma, as well as unique molecular characteristics of each condition remain unclear.

Very little is known about the heritability and genetic background of FGT polyps. Genetic factors, including chromosomal translocations in 6p21-22, 12q13-15, or 7q22 regions, may contribute to polypoid morphology (Dal Cin et al., 1995; Nijkang et al., 2019; Vieira et al., 2022), and genetic disorders like Lynch or Cowden syndrome have been reported to be accountable for the development of EPs (Vieira et al., 2022). However, a recent study by Sahoo et al. did not confirm the presence of chromosomal rearrangements in endometrial polyps (Sahoo et al., 2022).

Thus, the confirmed pathophysiology for the development of FGT polyps is still unknown. However, it can be assumed that the development and mechanism of polyps are multifactorial and can also depend on genetic predisposition. Thus far, the proposed genetic mechanisms are primarily based on small candidate gene studies and are inconclusive (Altaner et al., 2006; Pal et al., 2008; Banas et al., 2018; Doria et al., 2018; Takeda et al., 2019). Studies in other complex diseases have shown that genome-wide association studies (GWAS) can provide valuable insight into disease biology (Claussnitzer et al., 2016), but as far as we are aware, no large-scale GWAS have been published for FGT polyps. Therefore, we performed a GWAS meta-analysis to identify the genetic variants associated with FGT polyps, followed by numerous post-GWAS analyses to understand the shared and unique genetic underpinnings of FGT polyps and endometrial cancer. Ultimately, this knowledge can highlight potential clinical avenues for appropriate diagnosis and management of FGT polyps.

Materials and methods

Ethical approval

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

All Estonian Biobank (EstBB) participants have signed a broad informed consent form, and analyses were carried out under ethical approvals 1.1-12/624 and 1.1-12/2733 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) and data release application 6-7/GI/630 from the EstBB. For the FinnGen study, we used only publicly available GWAS summary statistics without individual-level data and thus, a separate ethics approval was not needed.

Study cohorts

Our analyses included a total of 25,100 women with polyps of the FGT (International Classification of Disease, ICD-10 diagnosis code N84) and 207,193 female controls (without

the N84 code) of European ancestry from two studies: summary level statistics from the FinnGen R7 data release (11,092 cases and 94,394 controls) and individual-level data from the EstBB (14,008 cases and 112,799 controls). In FinnGen, cases were defined using the ICD-10 code N84 or corresponding ICD-9 (6210, 6227, 6237, 6246) and ICD-8 (62520) codes. Similar to EstBB, controls were defined as women who did not have the abovementioned disease codes.

To increase study power, we did not distinguish between different types of FGT polyp location in our phenotype definition. However, according to the FinnGen Risteys browser (https://r7.risteys.finngen.fi/phenocode/N14 POLYPFEMGEN), 20% of FGT polyp cases were also cases for phenotype "Uterine polyps", while in the EstBB data, 70.5 % of N84 cases had a diagnosis for uterine polyps (as defined by the presence of the ICD-10 code N84.0). This most likely reflects differences in the source of phenotype information - FinnGen phenotype definitions mostly use hospital records and thus involve more severe cases, while the EstBB also uses primary care records.

Cohort-level analyses

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

The EstBB is a population-based biobank including more than 200,000 individuals (approximately 135,000 of them women) representing 20% of the Estonian adult population. Information on ICD codes is obtained via regular linking with the National Health Insurance Fund and other relevant databases. Individuals with ICD-10 code N84 (mean age at recruitment 49.2 years, standard deviation 12.1) were categorised as cases having been diagnosed with polyps of the genital tract, and all female biobank participants without the diagnosis were considered as controls (mean age at recruitment 44.3 years, sd 16.6). The genotyping procedure for EstBB has been described previously (Koel et al., 2023; Laisk et al., 2021; Pujol-Gualdo et al., 2022). Briefly, Illumina GSAv1.0, GSAv2.0, and GSAv2.0_EST arrays were used for the genotyping of biobank participants at the Core Genotyping Lab of the Institute of Genomics,

University of Tartu. Individuals with a call-rate less than 95% and sex mismatch between phenotypic and chromosomal data were excluded from the analysis. Before imputation, genotyped variants were filtered by applying criteria of call rate < 95%, Hardy-Weinberg equilibrium $P < 10^{-4}$ (for autosomal variants only), and minor allele frequency < 1%. Eagle v2.3 software was used for pre-phasing, and Beagle was used for imputation. The populationspecific imputation reference of 2297 whole genome sequencing samples was used. Association analysis was performed using REGENIE v2.2.4 with year of birth and 10 principal components as covariates in step I, and variants with a minor allele count < 5 were excluded by default. In downstream association analysis, poorly imputed variants with an INFO score < 0.4 were excluded.

For FinnGen, GWAS summary statistics from the R7 data release were used, and therefore, individual-level data was not available. The summary statistics were obtained from https://www.finngen.fi/en/access results, whereas the FinnGen cohort and the genotyping/data analysis details have been previously described in Kurki et al. (Kurki et al., 2023). To summarise, age, 10 principal components, and genotyping batch were used in REGENIE v2.0.2 analysis as covariates, and for FinnGen summary statistics, variants with a minor allele count > 5 and imputation INFO score > 0.6 were included.

GWAS meta-analysis

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

A meta-analysis using fixed-effects inverse variance weighting with genomic control was performed with the GWAMA v2.1 tool. The genome-wide significance level was set to $P < 5 \times 10^{-8}$. The genomic inflation factors (lambda) for the individual study summary statistics were 1.046 (EstBB) and 1.045 (FinnGen). Variants present in both cohorts (n = 12,363,169) were included in downstream analyses.

Annotation of GWAS signals

To annotate the GWAS signals and prioritise potential biologically relevant genes at associated loci, we adopted the following approach.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

First, we used the Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS) platform v1.5.2 to identify genetic association loci. FUMA is an online platform designed for the annotation, prioritisation, and interpretation of GWAS results that uses data from multiple databases to annotate GWAS signals (Watanabe et al., 2017). In the first step of this analysis, independent significant variants, lead signals and genomic risk loci were defined. Independent significant variants (IndSigSNPs) were defined as variants that were genome-wide significant (P $< 5 \times 10^{-8}$) and had a pairwise LD $r^2 < 0.6$, according to the 1000G EUR reference panel. From this subset, lead variants were derived. Finally, risk loci were defined from independent significant SNPs by merging LD blocks if they are less apart than r² < 0.6. Thus, a genomic risk locus can contain several lead SNPs and/or independent significant SNPs, depending on the size of the locus and the LD structure. Thereafter, potential significant candidate SNPs (GWAS meta-analysis P > 0.05) were determined to be in LD with any of the IndSigSNPs ($r^2 \ge 0.6$) within a 1Mb window and had a MAF of $\ge 1\%$. These candidate SNPs were subjected to further annotation using multiple databases such as Annotate Variation (ANNOVAR) (Wang et al., 2010), RegulomeDB scores (ranging from 1 to 7, where lower score indicates greater evidence for having regulatory function) (Boyle et al., 2012), and Combined Annotation-Dependent Depletion (CADD) (a continuous score showing how deleterious the SNP is to protein structure/function; scores >12.37 indicate potential pathogenicity) (Kircher et al., 2014), 15 chromatin states from the Roadmap Epigenomics Project (ENCODE Project Consortium, 2012; Roadmap Epigenomics Consortium et al., 2015), expression quantitative trait loci (eQTL) data (genotype-tissue expression (GTEx) v6 and v7) (GTEx Consortium, 2013) and 3D chromatin interactions from HI-C experiments of 21 tissues/cell types (Schmitt et al., 2016). This process provides information on the location,

functional impact, and potential regulatory effects of detected SNPs. For eQTL annotations, we focused on tissues similar to uterine/vaginal tissue (GTEx Consortium, 2020).

Using the lead signal identified by FUMA, we performed a look-up in the Open Targets genetics database (Ghoussaini et al., 2021). This database combines several layers of evidence across a wide range of cell types and tissues to generate an aggregate 'variant to gene' (V2G) score. The V2G score provides identification and correlation of likely causal variants and genes to prioritise the potential functional genes associated with the identified variants. V2G score aggregates several parameters like distance from the canonical transcript start site, eQTLs and protein QTLs (pQTLs) datasets, datasets for chromatin interactions and conformation, molecular phenotypes, and in silico functional predictions (using the Variant Effect Predictor or VEP score).

Briefly, we prioritised genes in the identified loci by selecting three genes having the highest V2G score. Then we additionally identified those loci where the GWAS signal includes a missense variant using annotation data from FUMA. To provide additional support for prioritisation and further explore regulatory effects, we looked at eQTL associations according to FUMA annotations, and if none were reported, we looked at potential chromatin interactions as these may also indicate regulatory effects. To gain insight into endometrial-specific eQTLs, we queried the candidate SNPs defined by FUMA in the endometrial eQTL database (Fung et al., 2018).

Gene-based testing

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

Analysis by Multi-marker Analysis of GenoMic Annotation (MAGMA) v1.6 (de Leeuw et al., 2015), with the default settings in FUMA (Watanabe et al., 2017), was used to perform gene-based association analysis to complement the single variant analyses. Gene-based analysis enables to detect the joint effect of multiple genetic variants and can thus increase the power to detect associations. Briefly, variants located in the gene body were assigned to protein-coding

genes (n = 18,895; Ensembl build 85), and the SNP P-values were merged into a gene test statistic using the SNP-wise mean model (de Leeuw et al., 2015). The level of genome-wide significance was set at $0.05/18,895 = 2.6 \times 10^{-6}$, taking into account the number of tested genes.

Genetic associations with other traits:

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

During the FUMA functional mapping, candidate SNPs were linked with the GWAS catalogue (https://www.ebi.ac.uk/gwas/, GWAS Catalogue e0_r2022-11-29, FUMA v1.5.1) to explore the association of genetic variants with previously published GWAS of different phenotypic traits.

Genetic correlation analysis

To estimate the genetic correlations between our FGT polyps meta-analysis and 1,335 other traits, we utilised the LD Score Regression method implemented in the Complex Traits Genetics Virtual Lab (CTG-VL) (https://genoma.io/) and 3 additional endometrial cancer traits available in the GWAS catalogue (accession codes GCST006464, GCST006465 and GCST006466) (Bulik-Sullivan et al., 2015). Statistical significance was determined by applying a multiple testing correction (FDR < 5%) using the p.adjust function in R v3.6.3.

Associations with other phenotypic traits

To determine the associations between ICD-10 diagnosis main codes and the N84 diagnosis of polyps in the FGT, we conducted an analysis using individual level data from the EstBB. Logistic regression was used to test the associations between N84 and other ICD-10 codes while controlling for age at recruitment and 10 genetic principal components to account for population stratification and avoid false associations due to ancestry/regional differences between cases and controls. Age was included as a covariate to account for incomplete electronic diagnosis data for older participants in the biobank. Our analysis was limited to the diagnosis main codes along with all the subcodes to increase the power of the data. Statistically significant associations were determined by applying Bonferroni correction (2000 tested ICD main codes, corrected P threshold of 2.5 x 10⁻⁵). Odds ratios (ORs) were calculated by the logistic regression method and represented as adjusted ORs. The resulted associations were filtered to remove the diagnoses related to exogenous factors (such as injuries, poisoning, accidents, assaults, etc. in the S, T, U, V, W, X, and Y subchapters) and the PheWAS library (https://github.com/PheWAS/PheWAS) was used to visualise the results. All analyses were performed using R v4.1.3

In the FinnGen data, we did not have access to the individual level data, but using the Risteys portal (https://r7.risteys.finngen.fi/phenocode/N14 POLYPFEMGEN), we explored the results of the survival analysis evaluating associations between FGT polyps and other selected phenotypes. A detailed description of the survival analysis can be found in the Risteys documentation (https://r7.risteys.finngen.fi/documentation), but briefly, this type of analysis tests the association between an exposure endpoint and an outcome endpoint. For example, in the context of FGT polyps, what is the association between a diagnosis of FGT polyp (exposure endpoint) and endometrial carcinoma (outcome endpoint).

Results

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

Summary of GWAS

GWAS of a total of 25,100 women with polyps of the FGT and 207,193 female controls revealed ten significant (P < 5 x 10⁻⁸) genomic risk loci and 23 independent signals (Fig. 1, Table 1). The strongest signal, rs1702136 ($P = 2.17 \times 10^{-19}$), was observed on chromosome 3, which is an intronic variant of the *EEFSEC* gene. The majority of the significant signals (91.3%) were either intronic or intergenic variants, whereas two signals, rs2277339 (P = 7.57 x 10^{-10}) and rs1265005 (P = 1.09 x 10^{-9} , in LD with rs805698, $r^2 = 0.75$) on chromosomes 12 and 10, respectively, were exonic missense variants.

Table 1. Summary statistics of significant genomic risk loci with lead SNP and independent significant SNP.

277

278

279

chr:pos:A1:A2	rsID of	P-value	OR (95%	IndSigSNP	Effect	Heter
	Lead SNP		CI)	s	Allele	ogene
	(effect				frequency	ity p-
	allele)				(Est/Fin)	value
3:128118711:A:	rs1702136	2.17 x 10 ⁻	0.90 (0.88-	rs1702136	0.75/0.75	0.99
G	(G)	19	0.92)	rs3732402		
				rs4857866		
				rs7650365		
				rs2999051		
				rs13095166		
				rs74924715		
				rs1735527		
8:116869477:C:	rs800578	4.91 x 10 ⁻	1.08 (1.05-	rs800578	0.24/0.26	0.90
Т	(T)	11	1.10)	rs2736213		
4:95731394:A:G	rs2865375	4.36 x 10 ⁻	0.93 (0.92-	rs2865375	0.54/0.52	0.45
	(A)	10	0.95)	rs10033997		
12:57146069:G:	rs2277339(7.57 x 10 ⁻	1.10 (1.06-	rs2277339	0.87/0.86	0.37
Т	T)	10	1.13)			
10:105585753:C	rs19309775	7.59 x 10 ⁻	0.83 (0.78-	rs19309775	0.97/0.95	0.92
:T	3 (C)	10	0.88)	3		
				rs17116149		
				rs7911816		
				rs11360949		
				6		
				rs1265005		
1:61592380:A:G	rs12751005	1.09 x 10 ⁻⁹	1.06 (1.04-	rs12751005	0.68/0.67	0.90
	(A)		1.09)			
13:41869725:A:	rs77478686	8.21 x 10 ⁻⁹	1.18 (1.12-	rs77478686	0.97/0.95	0.67
G	(G)		1.26)			

5:142162633:A:	rs7728894	1.84 x 10 ⁻⁸	0.93 (0.91-	rs7728894	0.73/0.75	0.60
G	(G)		0.96)			
5:1285974:A:C	rs7705526	2.33 x 10 ⁻⁸	0.94 (0.92-	rs7705526	0.68/0.68	0.45
	(C)		0.96)			
19:8786624:A:G	rs2967684	2.72 x 10 ⁻⁸	0.93 (0.90-	rs2967684	0.81/0.76	0.40
	(G)		0.95)			

^{*}Alleles presented in alphabetical order

281

282

290

291

292

293

294

295

296

297

298

IndSigSNPs: Independent significant SNP




Figure. 1. Manhattan plot for significant genomic risk loci identified for polyps of female genital tract. On the Manhattan plot, the x-axis represents chromosomes, while the y-axis represents $-\log 10$ (P-values) for the association of variants identified in polyps of the female genital tract. The horizontal red dashed line represents the genome-wide significance threshold $(P < 5 \times 10^{-8})$. The prioritised genes for each locus are labelled on the top, and genes associated with exonic missense variants are coloured red.

Functional annotation of associated variants and gene prioritisation

We performed a look-up in the Open Targets Genetics database to evaluate the functional association of identified genomic loci and potentially mapped genes reflected by the V2G score. We additionally highlighted those loci where the GWAS signal includes a missense variant using annotation data from FUMA (Table 2). Full details of gene prioritisation together with supporting evidence from FUMA eQTL and chromatin interaction mapping, can be found in Supplementary Table 1.

Table 2. Summary of gene prioritisation results

299

300

301

302

303

Locus	Lead variant	Highest V2G score	Exonic variants	Biological evidence
3:128118711: A:G	rs1702136	EEFSEC RPN1 DNAJB8	NA	EEFSEC potential endometrial cancer susceptibility gene (Kho et al., 2021)
8:116869477: C:T	rs800578	TRPS1	NA	Potential tumour suppressor candidate in endometrial cancer (Liang <i>et al.</i> , 2012)
4:95731394:A: G	rs2865375	BMPR1B PDLIM5 HPGDS	NA	BMPR1B is associated with female infertility. BMPR1B-AS1 facilitates endometrial cancer cell proliferation (Lai et al., 2022). Bmpr1B mutant mice exhibit a failure in endometrial gland formation (Yi et al., 2001)
12:57146069: G:T	rs2277339	PRIM1 STAT6 HSD17B6	PRIM1	Cell proliferation, DNA replication
10:105585753: C:T	rs193097753	STN1 SH3PXD2A SLK	COL17A1	Cellular migration, cellular differentiation, extracellular matrix organisation

1:61592380:A: G	rs12751005	NFIA	NA	NFIA is involved in cellular growth and proliferation, tumour morphology. The gene is expressed in endometrial tissue (Humaidan et al., 2012)
13:41869725: A:G	rs77478686	NAA16 MTRF1 KBTBD7	NA	Differential expression of <i>NAA16</i> is associated with the pathogenesis of endometriosis (She <i>et al.</i> , 2022)
5:142162633: A:G	rs7728894	ARHGAP26 FGF1 SPRY4	NA	ARHGAP26 promotes ovarian cancer cell invasion and migration (Chen et al., 2019)
5:1285974:A: C	rs7705526	TERT CLPTM1L SLC6A18	NA	TERT-CLPTM1L locus is a known susceptibility region for cancerous processes
19:8786624:A: G	rs2967684	ACTL9 NFILZ ADAMTS10	NA	ACTL9 locus associated with endometriosis (Rahmioglu et al., 2023)

Based on coding variants in our GWAS signals, we were able to prioritise PRIM1 and COL17A1 in loci on chromosomes 12 and 10, respectively. PRIM1 is a DNA primase involved in the initiation of DNA replication by synthesising RNA primers for Okazaki fragments during discontinuous DNA replication (Shiratori et al., 1995). rs2277339 is also a cis-eQTL for PRIM1 in endometrial tissue, which further supports PRIM1 as a candidate gene in this locus.

304

305

306

307

308

309

COL17A1, on the other hand, is primarily involved in cellular migration, cellular differentiation, and extracellular matrix organisation (Jones et al., 2020). While these genes have not yet been directly associated with FGT polyps, their biological functions, particularly those related to cellular proliferation, highlight their potential involvement in the development of polyps.

Several of the prioritised candidate genes had previously been associated with (endometrial) cancer - EEFSEC, TRPS1, TERT/CLPTM1L, one could be directly linked with endometrial biology (BMPR1B), and for the remaining, their biological significance in FGT polyps remains unclear.

Gene-based associations of female genital tract polyps:

To combine the joint effect of multiple genetic variants and increase the power to detect associations, we performed a MAGMA gene-based test implemented in FUMA. Eight genes were identified which passed the recommended threshold for significance ($P = 2.6 \times 10^{-6}$, Bonferroni correction for association testing of 18,895 protein-coding genes): EEFSEC, TERT, RUVBL1, BMPR1B, TRPS1, COL17A1, BET1L, WBP4 (Supplementary Figure 1, Supplementary Table 2). Majority of these associations mirror the genes prioritised in the single variant analysis, while the BET1L locus was not genome-wide significant in the single variant analysis and is thus novel. Previously, BET1L has been associated with endometrial cancer (Bateman et al., 2017) and uterine fibroids (Cha et al., 2011; Edwards et al., 2013; Liu et al., 2018).

GWAS catalogue look-up

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

We searched the GWAS catalogue for associations between previously published phenotypic traits and candidate SNPs identified by the FUMA tool to gain additional insight into their potential biological roles (Fig. 2, Supplementary Table 3). Based on the GWAS catalogue look-up, the TERT-CLPTM1L (rs7705526) locus was clearly associated with cancers,

335

336

337

338

339

340

341

342

343

344

18

including the development of reproductive cancers such as ovarian cancer and prostate cancer. Potential involvement in cancerous processes was also observed for the EEFSEC locus (rs4857866), which was associated with prostate cancer and also nominally with endometrial cancer (P < 1 x 10⁻⁶). Several identified signals were related to reproductive traits, including menarche (rs2277339-PRIM1), menopause (rs2277339-PRIM1), gestational age (rs4857866-EEFSEC) and uterine fibroids (rs2277339-PRIM1, rs193097753-COL17A1, rs17116149-COL17A1). The rs193097753 signal was additionally associated with the known risk factors for the development of FGT polyps, such as type 2 diabetes ($P < 5 \times 10^{-8}$) and waist-to-hip ratio $(P < 2 \times 10^{-11})$, further substantiating its functional significance.




Figure. 2: GWAS catalogue look-up showing associations between genetic variants associated with female genital tract polyps and other phenotypes. The figure highlights the genome-wide significant ($P < 5 \times 10^{-8}$) association between FGT polyps genetic risk factors (individual significant SNPs) and previously published phenotypic traits and disorders.

Look-up of variants associated with endometrial cancer

346

347

348

349

350

351

352

353

Since there is some overlap between FGT polyp genetic risk loci and those known to be associated with (endometrial) cancer, we conducted a look-up of variants associated with endometrial cancer (O'Mara et al., 2018) in our GWAS data. Of the 19 SNPs queried, seven

were nominally significant (P < 0.05) (rs9668337-SSPN, rs1740828-SOX4, rs17601876-CYP19A1, rs882380-SNX11, rs3184504-SH2B3, rs1129506-EVI2A, rs11263761-HNF1B) in the FGT polyp analysis as well (Supplementary Table 4). When querying the 10 lead variants associated with FGT polyp in the endometrial cancer summary statistics, we observed that three were nominally significant (P < 0.05) in the endometrial cancer and also in the endometrial cancer with endometrioid histology studies (rs1702136-EEFSEC, rs2865375-BMPR1B, rs7705526-TERT).

Genetic correlation between FGT polyps and other traits

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

We conducted pairwise genetic correlation (rg) analyses to examine the relationship between polyps of the FGT and 1,335 different traits obtained from the Complex Traits Genetics Virtual Lab (CTG-VL, https://genoma.io/) and 3 additional endometrial cancer traits available in the GWAS catalogue (accession codes GCST006464, GCST006465 and GCST006466). After running the analysis and correcting for multiple testing, we identified a total of 11 significant (FDR < 0.05) genetic correlations. Selected genetic correlations between polyps and various phenotypic categories such as anthropometrics, cardiovascular diseases, genitourinary traits, mood disorders, sex hormones and surgical procedures are displayed in Fig. 3, full results in Supplementary Table 5. As expected, a positive genetic correlation was observed with genitourinary traits and hysterectomy, emphasising that polyps are commonly occurring incidental findings in gynaecological disorders. Furthermore, sex hormone-binding globulin (SHBG) was negatively correlated with the risk of FGT polyps. We were not able to detect a significant genetic correlation between FGT polyps and estradiol level or BMI, known risk factors of FGT polyps, in our dataset. FGT polyps showed weak correlation with two of the three endometrial cancer phenotypes tested (endometrial cancer and endometrial cancer endometrioid histology, both rg 0.25-0.27, se 0.12-0.13), but these associations were only nominally significant (P = 0.03) and did not pass multiple testing correction threshold.




Figure 3: Results of genetic correlation analysis between endometrial polyps and other relevant traits.

The plot displays selected genetic correlations between female genital tract polyps and traits from various phenotypic categories such as anthropometrics, cardiovascular traits, genitourinary traits, mood disorders, sex hormones and surgical procedures that are colourcoded. Significant associations after FDR multiple correction are shown in the lower panel, while the upper panel shows selected traits of interest that do not pass the multiple testing correction. The centre dot marks the estimated genetic correlation (rg) value, and error bars indicate 95% confidence limits. The dotted red line indicates no genetic correlation.

Associations between polyps of FGT and other diagnosis codes

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

Additionally, to evaluate other phenotypes' association with FGT polyps, we performed a phenome-wide phenotype association analysis using the EstBB data for disease codes. All 239 phenotypic associations with a $P < 2.5 \times 10^{-5}$ (corresponding to a Bonferroni-corrected threshold of 0.05/2020) are shown in Supplementary Table 6. The most significant association of FGT polyps related to other phenotypes were: i) leiomyoma of uterus (D25), which are

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

22

uterine fibroids known to often occur together with EPs (Kınay et al., 2016); ii) endometriosis (N80), which has been correlated with a high prevalence of endometrial polyps; iii) excessive, frequent and irregular menstruation (N92) which is one of the classical symptoms of EPs, and; iv) other noninflammatory disorders of uterus except cervix (N85) (Fig. 4). Moreover, women with a diagnosis for FGT polyps had significantly more diagnoses for benign neoplasms in several tissues, such as the uterus (D26), ovary (D27), unspecified female genital organs (D28 and D39) and skin (D23) as well as malignant neoplasms of the uterus (C54) and skin (C44). In our analysis, nasal polyps (J33) and K62 (which includes anal/rectal polyps) were also nominally significant, which supports the idea of some systemic tissue overgrowth in epithelial tissues similar to endometrial polyps harbouring glandular and luminal epithelium.

For the highlighted associations, we queried the FinnGen Risteys R7 portal to see if we observe similar associations in the Finnish data. While the analysis in the Estonian data does not consider which diagnosis in the tested pair comes first, the FinnGen data survival analysis tests the association in both directions. Uterine leiomyoma, endometriosis, other benign neoplasm of uterus, benign neoplasm of ovary, malignant neoplasm of uterus, and carcinoma in situ of endometrium were significantly associated with FGT polyps in the survival analysis in FinnGen data, (Supplementary Table 7) both if the diagnosis occurred before, or after the FGT polyp diagnosis.

The results of phenotypic associations of FGT polyps are in concordance with the observed genetic associations and point to the fact that benign and cancerous processes share some mechanisms (such as cellular proliferation) on a genetic level.




Figure 4: Association of Polyps of female genital tract (N84) with other phenotypes.

Each triangle in the plot corresponds to one ICD10 main code, and different colours represent different diagnosis categories. The direction of the triangle represents the direction of effect and upward-pointing triangles show increased significance of diagnosis code in female genital tract polyps. The red line indicates the Bonferroni corrected threshold for statistical significance.

Discussion

419

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

Gynaecological polyps are a common diagnosis in women, with potential negative implications for women's reproductive health and well-being. We conducted the first largescale GWAS meta-analysis to study the genetic underpinnings of FGT polyps and their association with other phenotypic traits from two European ancestry biobanks. The analysis revealed ten genomic risk loci, of which two (rs2277339 and rs193097753) tagged exonic missense variants suggestive of plausible functional importance in the development of polyps. Furthermore, several of the identified genetic risk loci have previously been associated with (endometrial) cancer and/or uterine fibroids. Genetic correlation analysis additionally showed negative correlation with SHBG levels, but no statistically significant genome-wide correlation

with endometrial cancer. PheWAS analysis showed an increased prevalence of endometriosis, irregular and excessive menstruation, uterine fibroids and neoplasms of the uterus and other tissues in women with FGT polyps.

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

Even though most EPs are benign, there is still a certain level of risk these polyps may progress to malignant transformation (Antunes et al., 2007; Lenci et al., 2014). According to a systematic review and meta-analysis, 2.7%-3.6% of EPs can be considered malignant, with significant heterogeneity in prevalence among pre- and postmenopausal women (Lee et al., 2010; Sasaki et al., 2018; Uglietti et al., 2019). While we saw no statistically significant genetic correlation between FGT polyps and endometrial cancer, several of the mapped genetic risk loci/prioritised genes (rs1702136-EEFSEC, rs800578-TRPS1, rs2865375-BMPR1B, and rs7705526-TERT-CLPTM1L) have previously been associated with cancer either in GWAS or functional studies (Liang et al., 2012; Wu et al., 2014; Kho et al., 2021; Dos Santos et al., 2022), most likely reflecting the fact that both benign and malignant tissue overgrowths may utilise the same cellular mechanisms to some extent. This is supported by the results of the associated diagnoses analysis where women with a diagnosis of FGT polyp also have more diagnoses related to benign and malignant neoplasms of the uterus, ovary, and skin. While the associations with reproductive tract neoplasms may arise due to incidental findings during diagnostic procedures, it cannot be ruled out that some women have a genetic predisposition to tissue overgrowth that may manifest in either benign or malignant neoplasms in certain tissues. Apart from a few small-scale reports (Unler et al., 2016), there are no relevant studies evaluating the prevalence of different neoplasms among women with FGT polyps, therefore, our observations need to be confirmed and further evaluated in future studies.

We further saw significant associations of FGT polyps with uterine leiomyoma and endometriosis. Though the cellular composition, characteristics, and mechanism of origin of uterine fibroids and endometrial polyps differ from each other, they can occur concurrently due

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

25

to common risk factors like advanced age, obesity, and hormonal dysregulation (Kınay *et al.*, 2016; Pavone *et al.*, 2018). Further, increased prevalence of endometriosis among women with FGT polyps emphasises the reported evidence of a higher prevalence of endometrial polyps in endometriosis patients (Shen *et al.*, 2011; Zhang *et al.*, 2018; Lin *et al.*, 2020; Peters *et al.*, 2022).

Our genetic correlation analysis showed a significant negative correlation between SHBG levels and the risk of FGT polyps. In females, testosterone and oestrogen levels are regulated through their binding to SHBG, which helps maintain hormonal balance in the bloodstream. Lower levels of SHBG can result in elevated levels of free testosterone and free oestrogen. As EPs are oestrogen dependent, lower SHBG may directly stimulate EP development. Moreover, the expression of aromatase 450 enzyme in the EPs, converts free testosterone into oestrogen, further augments the stimulation of polyps' development (Filho et al., 2007). Thus, our study's finding of the negative correlation of SHBG in FGT polyps concords with this mechanism. Unexpectedly, our analysis did not reveal a genetic correlation between oestradiol and EPs. The discrepancy between circulating plasma levels and localized endometrial levels of oestradiol may underlie the lack of this correlation. In the literature, serum levels of oestradiol were shown to be significantly lower (five times) than the endometrial oestradiol concentration in the proliferative phase (Huhtinen et al., 2012). The same trend was observed in women with abnormal uterine bleeding and hyperplasia (Cortés-Gallegos et al., 1975). Given that abnormal bleeding and hyperplasia are important symptoms of endometrial polyps, it suggests that localised oestradiol may play a more crucial role in EP development. Additionally, a study reported no significant difference in circulating oestradiol concentration among women with and without endometrial polyps (Cortés-Gallegos et al., 1975), which further supports our finding. This can also explain the lack of correlation of FGT polyps with

BMI to some extent, as higher BMI is often associated with increased circulating oestradiol levels.

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

To understand how genetic variation impacts trait susceptibility, it is important to link associated genetic variants with specific genes and mechanisms. We employed a diverse range of data layers to map potential candidate genes for the identified genomic loci. Among others, PRIM1 (rs2277339) and COL17A1 (rs193097753) were prioritised since the GWAS signals tagged coding variants in these genes. In the literature, neither of these genes has been directly correlated with FGT development. The PRIM1 gene is a key regulator of DNA replication during cellular proliferation process. It has been shown that the PRIM1 expression was upregulated in breast tumour tissues compared to healthy tissues, and its inhibition led to tumour cell growth regression (Lee et al., 2019). Furthermore, the PRIM1-induced tumour cell growth is stimulated by oestrogen through activation of the oestrogen receptor (ER) (Lee et al., 2019). As per one of the postulated hypotheses, polyp development is related to oestrogen stimulation with predominantly increased ER alpha (ER-alpha) and decreased progesterone receptors (PRs) A and B in the glandular epithelium. On the other hand, in the stromal cells of polyps, lower concentrations of ER and PR hinder the decidualization process, preventing them from shedding off during menstruation (Mittal et al., 1996; Peng et al., 2009; Nijkang et al., 2019). Since the *PRIM1* gene signalling is oestrogen-associated, this can provide important insights into the probable functional mechanisms underlying the development of polyps. The COL17A1 gene is closely associated with epithelial tumour progression and invasiveness (Jones et al., 2020), suggesting that a shared biological mechanism related to epithelial cell proliferation could be associated with the development of EPs. However, further functional assays on *PRIM1* and *COL17A1* genes are needed to confirm these associations.

While our study is a large-scale study, it had certain limitations. The cohort from Estonian and Finnish biobanks encompasses women with all kinds of reproductive polyps, and

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

phenotype data.

our phenotype definition did not differentiate between the types/location of polyps to increase study sample size power. However, considering the overall occurrence of polyps in the general population, endometrial polyps would be more prevalent than the other types. A complete understanding of the transcriptome profile of endometrial polyps is still lacking, resulting in knowledge gaps regarding the interplay between genomic loci and the regulation of gene expression. By addressing these knowledge gaps, we can gain valuable insights into the genetic factors and gene expression patterns that contribute to the pathogenesis of endometrial polyps and potentially identify novel therapeutic targets for their management. In conclusion, the first GWAS meta-analysis of FGT polyps highlights and clarifies the genetic mechanisms shared between EP development (tissue overgrowth) and cancerous processes. Furthermore, an analysis of associated diagnoses showed that women diagnosed with EPs have an increased prevalence of other diagnoses, such as endometriosis, uterine fibroids and both benign and malignant neoplasms, which could have implications for patient management and counselling. **Supplementary data:** Supplementary data are available at Human reproduction online. **Data availability:** FinnGen cohort level summary statistics can be accessed as described here: https://www.finngen.fi/en/access_results. Protocol for accessing the Estonian Biobank data is described here: https://genomics.ut.ee/en/content/estonian-biobank. GWAS meta-analysis summary statistics will be made available via the GWAS Catalogue (data upload pending). Author's roles: Authors A.D.S.P., N.P.G, A.S., M.P and T.L. participated in the conception of the study, data analysis, and interpretation of the data, and writing the manuscript. V.R., J.D., and R.M. contributed to data analysis and interpretation. T.L., M.S., M.P., V.R., J.D. and A.S. critically reviewed and provided feedback on each version of the manuscript and all the authors approved the final version. The EstBB Research Team provided the EstBB genotype and

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

Acknowledgements: We want to acknowledge the participants of the Estonian Biobank and the participants and investigators of the FinnGen study. We also acknowledge the Estonian Biobank Research team members Andres Metspalu, Tonu Esko, Mari Nelis, Georgi Hudjashov, and Lili Milani. Funding: N.P.G. was supported by MATER Marie Sklodowska-Curie which received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 813707. T.L. was supported by the Estonian Research Council grant PSG776. This study was funded by European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED. Computations were performed in the High-Performance Computing Center of University of Tartu. The study was also supported by the Estonian Research Council (grant no. PRG1076 and MOBJD1056) and Horizon 2020 innovation grant (ERIN, grant no. EU952516). **Conflict of interest:** All the authors declared no conflict of interest. **References:** Altaner S, Gucer F, Tokatli F, Guresci S, Ozdemir C, Puyan FO, Kutlu K. Expression of Bcl-2 Ki-67 in tamoxifen-associated endometrial polyps: comparison with postmenopausal polyps. *Onkologie* 2006;**29**:376–380. Annan JJ, Aquilina J, Ball E. The management of endometrial polyps in the 21st century. *The* Obstetrician & Gynaecologist 2012;14:33–38. Antunes A, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in preand postmenopausal women: factors associated with malignancy. Maturitas 2007;**57**:415–421.

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

Azevedo JM da R de, Azevedo LM da R de, Freitas F, Wender MCO. Endometrial polyps: when to resect? Arch Gynecol Obstet 2016;293:639-643. Banas T, Pitynski K, Mikos M, Cielecka-Kuszyk J. Endometrial Polyps and Benign Endometrial Hyperplasia Have Increased Prevalence of DNA Fragmentation Factors 40 and 45 (DFF40 and DFF45) Together With the Antiapoptotic B-Cell Lymphoma (Bcl-2) Protein Compared With Normal Human Endometria. Int J Gynecol Pathol 2018;**37**:431–440. Bateman NW, Dubil EA, Wang G, Hood BL, Oliver JM, Litzi TA, Gist GD, Mitchell DA, Blanton B, Phippen NT, et al. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. Cancer 2017;**123**:4004–4012. Bettocchi S, Achilarre M, Ceci O, Luigi S. Fertility-Enhancing Hysteroscopic Surgery. Semin Reprod Med 2011;29:075-082. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22:1790–1797. Cha P-C, Takahashi A, Hosono N, Low S-K, Kamatani N, Kubo M, Nakamura Y. A genomewide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet 2011;43:447-450. Chen X, Chen S, Li Y, Gao Y, Huang S, Li H, Zhu Y. SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration. Exp Mol Med 2019;**51**:1–12. Dal Cin P, Vanni R, Marras S, Moerman P, Kools P, Andria M, Valdes E, Deprest J, Van de Ven W, Van den Berghe H. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res 1995;55:1565–1568.

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

Doria PLS, Moscovitz T, Tcherniakovsky M, Fernandes CE, Pompei LM, Wajman M, Nimwegen AV, Haimovich S. Association of IGF-1 CA(n) and IGFBP3 rs2854746 Polymorphisms with Endometrial Polyp Risk. *Biomed Res Int* 2018;**2018**:8704346. Dos Santos GA, Viana NI, Pimenta R, Camargo JA de, Guimaraes VR, Romão P, Candido P, Ghazarian V, Reis ST, Leite KRM, et al. Pan-cancer analysis reveals that CTC1-STN1-TEN1 (CST) complex may have a key position in oncology. Cancer Genet 2022;262– **263**:80–90. Dreisler E, Stampe Sorensen S, Ibsen PH, Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. *Ultrasound Obstet* Gynecol 2009;33:102-108. Edwards TL, Hartmann KE, Velez Edwards DR. Variants in BET1L and TNRC6B associate with increasing fibroid volume and fibroid type among European Americans, Hum Genet 2013;**132**:1361–1369. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74. Fatemi HM, Kasius JC, Timmermans A, Disseldorp J van, Fauser BC, Devroey P, Broekmans FJ. Prevalence of unsuspected uterine cavity abnormalities diagnosed by office hysteroscopy prior to in vitro fertilization. *Hum Reprod* 2010;**25**:1959–1965. Filho AMB de B, Barbosa IC, Maia H, Genes CC, Coutinho EM. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women. Gynecol Endocrinol 2007;23:511-517. Fung JN, Mortlock S, Girling JE, Holdsworth-Carson SJ, Teh WT, Zhu Z, Lukowski SW, McKinnon BD, McRae A, Yang J, et al. Genetic regulation of disease risk and endometrial gene expression highlights potential target genes for endometriosis and polycystic ovarian syndrome. Sci Rep 2018;8:11424.

615 Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L, Miranda 616 A, Carvalho-Silva D, Buniello A, et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic 617 618 Acids Res 2021;49:D1311–D1320. 619 GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580– 585. 620 621 Hinckley MD, Milki AA. 1000 office-based hysteroscopies prior to in vitro fertilization: 622 feasibility and findings. JSLS 2004;8:103–107. 623 Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel 624 L, Devroey P, Fatemi H. Endometrial gene expression in the early luteal phase is 625 impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH 626 antagonist co-treated IVF cycles. *Hum Reprod* 2012;**27**:3259–3272. 627 Jones VA, Patel PM, Gibson FT, Cordova A, Amber KT. The Role of Collagen XVII in Cancer: 628 Squamous Cell Carcinoma and Beyond. Front Oncol 2020;10:352. 629 Karayalcin R, Ozcan S, Moraloglu O, Ozyer S, Mollamahmutoglu L, Batıoglu S. Results of 630 2500 office-based diagnostic hysteroscopies before IVF. Reprod Biomed Online 631 2010;**20**:689–693. 632 Kho PF, Wang X, Cuéllar-Partida G, Dörk T, Goode EL, Lambrechts D, Scott RJ, Spurdle AB, 633 O'Mara TA, Glubb DM. Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial 634 635 cancer susceptibility. Commun Biol 2021;4:1211. 636 Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for 637 estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;**46**:310–315. 638

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

Kınay T, Öztürk Basarır Z, Fırtına Tuncer S, Akpınar F, Kayıkçıoğlu F, Koc S. Prevalence of endometrial polyps coexisting with uterine fibroids and associated factors. Turk J Obstet *Gynecol* 2016;**13**:31–36. Koel M, Võsa U, Jõeloo M, Läll K, Gualdo NP, Laivuori H, Lemmelä S; Estonian Biobank Research Team; FinnGen; Daly M, et al. GWAS meta-analyses clarify the genetics of cervical phenotypes and inform risk stratification for cervical cancer. Hum Mol Genet. 2023,**32**:2103-2116. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, et al. FinnGen provides genetic insights from a wellphenotyped isolated population. *Nature* 2023;613:508–518. Lai T, Qiu H, Si L, Zhen Y, Chu D, Guo R. Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway. *Cell Cycle* 2022;**21**:1599–1618. Laisk T, Lepamets M, Koel M, Abner E, Estonian Biobank Research Team, Mägi R. Genomewide association study identifies five risk loci for pernicious anemia. Nat Commun 2021;**12**:3761. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol 2010:116:1197–1205. Lee W-H, Chen L-C, Lee C-J, Huang C-C, Ho Y-S, Yang P-S, Ho C-T, Chang H-L, Lin I-H, Chang H-W, et al. DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint. Int J Cancer 2019;144:615-630. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of

GWAS data. *PLoS Comput Biol* 2015;**11**:e1004219.

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

Lenci MA, Nascimento VAL do, Grandini AB, Fahmy WM, Depes D de B, Baracat FF, Lopes RGC. Premalignant and malignant lesions in endometrial polyps in patients undergoing hysteroscopic polypectomy. Einstein (Sao Paulo) 2014;12:16–21. Liang H, Cheung LWT, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012;22:2120-2129. Lin S, Xie X, Guo Y, Zhang H, Liu C, Yi J, Su Y, Deng Q, Zhu W. Clinical characteristics and pregnancy outcomes of infertile patients with endometriosis and endometrial polyps: A retrospective cohort study. *Taiwan J Obstet Gynecol* 2020;**59**:916–921. Liu B, Wang T, Jiang J, Li M, Ma W, Wu H, Zhou Q. Association of BET1L and TNRC6B with uterine leiomyoma risk and its relevant clinical features in Han Chinese population. Sci Rep 2018;8:7401. Mittal K, Schwartz L, Goswami S, Demopoulos R. Estrogen and progesterone receptor expression in endometrial polyps. *Int J Gynecol Pathol* 1996;**15**:345–348. Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H, Urbanski LM, Curimjee N, Berger AC, Gao GF, et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun 2020;11:2517. Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae and treatment. SAGE Open Med 2019;7:2050312119848247. O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 2018;9:3166. Pal L, Niklaus AL, Kim M, Pollack S, Santoro N. Heterogeneity in endometrial expression of aromatase in polyp-bearing uteri. Hum Reprod 2008;23:80–84.

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

3

Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol 2018;46:3–11. Peng X, Li T, Xia E, Xia C, Liu Y, Yu D. A comparison of oestrogen receptor and progesterone receptor expression in endometrial polyps and endometrium of premenopausal women. J Obstet Gynaecol 2009;29:340–346. Peters M, Mikeltadze I, Karro H, Saare M, Estonian Biobank Research Team, Salumets A, Mägi R, Laisk T. Endometriosis and irritable bowel syndrome: similarities and differences in the spectrum of comorbidities. *Hum Reprod* 2022;**37**:2186–2196. Pujol-Gualdo N, Läll K, Lepamets M, Estonian Biobank Research Team, Rossi H-R, Arffman RK, Piltonen TT, Mägi R, Laisk T. Advancing our understanding of genetic risk factors and potential personalized strategies for pelvic organ prolapse. Nat Commun 2022;**13**:3584. Rahmioglu N, Mortlock S, Ghiasi M, Møller PL, Stefansdottir L, Galarneau G, Turman C, Danning R, Law MH, Sapkota Y, et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. *Nat Genet* 2023;**55**:423–436. Raz N, Feinmesser L, Moore O, Haimovich S. Endometrial polyps: diagnosis and treatment options - a review of literature. Minim Invasive Ther Allied Technol 2021;30:278–287. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, et al. Integrative analysis of 111 reference human epigenomes. *Nature* 2015;**518**:317–330. Sahoo SS, Aguilar M, Xu Y, Lucas E, Miller V, Chen H, Zheng W, Cuevas IC, Li H-D, Hitrys D, et al. Endometrial polyps are non-neoplastic but harbor epithelial mutations in

endometrial cancer drivers at low allelic frequencies. *Mod Pathol* 2022;**35**:1702–1712.

711 Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley M da S, Pereira MG. Factors 712 Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol 2018;25:777–785. 713 714 Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, Li Y, Lin S, Lin Y, Barr CL, et al. A 715 Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the 716 Human Genome. Cell Rep 2016;17:2042–2059. 717 She J, Su D, Diao R, Wang L. A Joint Model of Random Forest and Artificial Neural Network 718 for the Diagnosis of Endometriosis. Front Genet 2022;13:848116. Shen L, Wang Q, Huang W, Wang Q, Yuan Q, Huang Y, Lei H. High prevalence of endometrial 719 720 polyps in endometriosis-associated infertility. Fertil Steril 2011;95:2722-2724.e1. 721 Shiratori A, Okumura K, Nogami M, Taguchi H, Onozaki T, Inoue T, Ando T, Shibata T, Izumi 722 M, Miyazawa H. Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and 723 PRIM2B) subunit genes of the human DNA primase to chromosome bands 1q44 and 724 6p11.1-p12. Genomics 1995;28:350-353. 725 Takeda T, Banno K, Kobayashi Y, Adachi M, Yanokura M, Tominaga E, Kosaki K, Aoki D. 726 Mutations of RAS genes in endometrial polyps. *Oncol Rep* 2019;**42**:2303–2308. Tanos V, Berry KE, Seikkula J, Abi Raad E, Stavroulis A, Sleiman Z, Campo R, Gordts S. The 727 728 management of polyps in female reproductive organs. Int J Surg 2017;43:7–16. 729 Uglietti A, Buggio L, Farella M, Chiaffarino F, Dridi D, Vercellini P, Parazzini F. The risk of 730 malignancy in uterine polyps: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2019;237:48-56. 731 732 Unler GK, Gokturk HS, Toprak E, Erinanc OH, Korkmaz H. Does the Presence of Endometrial Polyp Predict Colorectal Polyp? Am J Med Sci 2016;351:129–132. 733

734 Vieira MDC, Vitagliano A, Rossette MC, Neto LC de A, Gallo A, Sardo ADS. Endometrial 735 Polyps: Update Overview on Etiology, Diagnosis, Natural History and Treatment. CEOG 2022;49:232. IMR Press. 736 737 Vitale SG, Haimovich S, Laganà AS, Alonso L, Di Spiezio Sardo A, Carugno J, From the Global Community of Hysteroscopy Guidelines Committee. Endometrial polyps. An 738 739 evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol 740 2021;**260**:70–77. 741 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164. 742 743 Watanabe K, Taskesen E, Bochoven A van, Posthuma D. Functional mapping and annotation 744 of genetic associations with FUMA. Nat Commun 2017;8:1826. 745 Wu L, Wang Y, Liu Y, Yu S, Xie H, Shi X, Qin S, Ma F, Tan TZ, Thiery JP, et al. A central 746 role for TRPS1 in the control of cell cycle and cancer development. Oncotarget 747 2014;**5**:7677–7690. 748 Yi SE, LaPolt PS, Yoon BS, Chen JY, Lu JK, Lyons KM. The type I BMP receptor BmprIB is 749 essential for female reproductive function. Proc Natl Acad Sci U S A 2001;98:7994-750 7999. 751 Zhang Y-N, Zhang Y-S, Yu Q, Guo Z-Z, Ma J-L, Yan L. Higher Prevalence of Endometrial 752 Polyps in Infertile Patients with Endometriosis. Gynecol Obstet Invest 2018;83:558– 753 563. 754 755 756 757

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781